Our community is involved in the first clinical trial of a targeted therapy for myotonic dystrophy, and a number of other critical studies are underway. Click on the links below and to the right to learn more about the clinical trials process, important do's and don'ts for current trial participants, and more. A list of current studies and trials can be accessed below.
Myotonic Dystrophy Foundation community members have been active partners in bringing the research to this point, by supporting and participating in studies, joining registries, responding to surveys, and funding patient advocacy organizations like the MDF. The progress achieved would not be possible without the commitment and participation of people living with DM, their families, caregivers and friends.
Questions?
If you don’t see answers to your specific questions here, please send MDF an email. Keep in mind that some of your questions may not be answerable right now, either because the information is proprietary, could impact the success of trials if released, or isn’t known yet.
Current Studies and Trials
Current trial participants should view our short Clinical Trials Training Video to familiarize yourself with the clinical trials process and important do's and don'ts, such as what content is appropriate to share publicly.
We strongly encourage you to join registries, including the Myotonic Dystrophy Family Registry and the DM and FSHD Registry at the University of Rochester, and make sure you update your information annually. You also may have an opportunity to participate in biobanks and follow organizations like the Myotonic Dystrophy Foundation to make sure you have current information regarding progress and research needs.
Visit the full Study & Trial Resource Center to find additional resources for participants as well as a list of frequently asked questions.
See the list below for information on current studies and trials.
Status
Study
Status: Enrolling by invitation
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Conditions: Myotonic Dystrophy Type 1
Location: Multiple sites
Sponsor: Myotonic Dystrophy Clinical Research Network
Contact: Co-PIs Drs. Charles Thornton and Nicholas Johnson; see site-specific contact information below
If you are interested in this research study, please contact one of the study coordinators listed below or or Jeanne Dekdebrun at Jeanne_Dekdebrun@urmc.rochester.edu or Jessica St. Romain at Mary.StRomain@vcuhealth.org.
Recruiting:
-
University of Kansas, Kansas City, Kansas
Katie Roath, kroath@kumc.edu / 913-945-9928 -
University of Rochester, Rochester, New York
Jeanne Dekdebrun, dekdegbrun@urmc.rochester.edu / 585-276-4611 -
Virginia Commonweatlh University, Richmond, Virginia
Jodie Howell, Jodie.Howell@vcuhealth.org / 804-628-6480 -
Ohio State University, Columbus, Ohio
Alison Sankey, Alison.Sankey@osumc.edu / 614-688-7812 -
University of Florida, Gainesville, Florida
Jaime Bolling, Jamie.Bolling@neurology.ufl.edu / (352) 733-2432 -
Houston Methodist, Houston, Texas
Isaiah Carter, iccarter@houstonmethodist.org / 713-441-5192 -
Stanford University, Stanford, California
Lesly Welsh, lwelsh@stanford.edu / 650-497-3079 -
University of Iowa, Iowa City, Iowa
Nicole Kressin, nicole-kressin@uiowa.edu / 319-678-8596 -
National Institutes of Health, Bethesda, Maryland
Vanessa Ndege, vanessa.ndege@nih.gov / 301-435-9319 -
Institut de Myologie, Paris, France
Guillaume Bassez, MD, guillaume.bassez@aphp.fr -
Centro Clinico NEMO, Milan, Italy
Luca Mauro, luca.mauro@centrocliniconemo.it / +39 02 91433264 -
Radboud University, Nijmegen, Netherlands
Baziel vanEngelen, MD, baziel.vanengelen@radboudumc.nl / (024) 366 8374 -
Ludwig Maximilian University of Munich, Munich, Germany
Stephan Wenninger, Stephan.Wenninger@med.uni-muenchen.de -
University College London, London, United Kingdom
Chris Turner, PhD, chris.turner7@nhs.net -
University of California Los Angeles, Los Angeles, California
Jennifer Huynh, JenniferH@mednet.ucla.edu / (310) 825-3264 -
University Colorado Denver, Aurora, Colorado
Brianna Blume, NeurologyResearchPartners@ucdenver.edu / 303-724-4644 -
Auckland Direct Health Board, Auckland, New Zealand
Miriam Rodrigues, MRodrigues@adhb.govt.nz / 021896662
Status: Partial Hold
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients (MARINA)
Conditions: Myotonic Dystrophy Type 1
Location: Multiple sites
Sponsor: Avidity Biosciences, Inc.
Contact: Avidity Biosciences, Inc.at 858-771-7038 or by email at medinfo@aviditybio.com.
Recruiting:
-
University of California Los Angeles (UCLA), Los Angeles, California
-
Stanford University, Palo Alto, California
-
University of Florida, Gainesville, Florida
-
Kansas University Medical Center, Kansas City, Kansas
-
University of Rochester Medical Center, Rochester, New York
-
Ohio State University, Columbus, Ohio
-
Virginia Commonwealth University, Richmond, Virginia
Not yet recruiting:
-
University of Colorado, Denver, Colorado
Status: Recruiting
Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1
Conditions: Myotonic Dystrophy Type 1
Location: Multiple sites
Sponsor: Harmony Biosciences, LLC
Contact: Ann Adee at 773-383-6258, Michelle Manuel at 847-903-4610, or email clinicaltrials@harmonybiosciences.com. See site-specific contact information below
Recruiting:
-
University of California Irvine, Irvine, CA
Janelle Rodriguez, janelr2@hs.uci.edu, 949-824-3485 and Mercedes Herrera, mercedh1@hs.uci.edu, 714-509-2665 -
University of Colorado, Aurora, CO
Brenna Baines, NeuroResearch@CUAnschutz.edu, 303-724-2207 and Alexis Shepardson, NeuroResearch@CUAnschutz.edu, 303-724-7248 -
University of South Florida, Tampa, FL
Jessica Shaw, jessshaw@usf.edu -
Rare Disease Research, Atlanta, GA
Brenda Almaras, brenda.almaras@rarediseaseresearch.com, 678-883-6897 -
Indiana University, Indianapolis, IN
Patti Hogan, hoganpr@iu.edu, 317-963-7455 -
University of Kansas Medical Center, Kansas City, KS
Kaylene Whited, kwhited2@kumc.edu, 913-574-0009 -
Kennedy Krieger Institute Center for Genetic Muscle Disorders, Baltimore, MD
Georgina D’Sanson, dsanson@kennedykrieger.org -
Massachusetts General Hospital, Boston, MA
Melina Durson, bdurson@bwh.harvard.edu -
University of Rochester Medical Center, Rochester, NY
Elizabeth Luebbe, Elizabeth_Luebbe@URMC.Rochester.edu -
Wake Forest, Winston-Salem, NC
Carolina Burgos, caguilar@wakehealth.edu, 336-713-2603 -
Ohio Sleep Medicine and Neuroscience Institute, Dublin, OH
Michelle Moffo, mmoffo@sleepmedicine.com, 614-766-0773 x170 -
NEW University of Cincinnati, Cincinnati, OH
Ashley Smith, Ashley.fisher@uc.edu, 513-558-4874 -
University of Pennsylvania, Philadelphia, PA
Pranali Ravikumar, pranali.ravikumar@pennmedicine.upenn.edu, 215-615-0550 -
University of Florida, Gainesville, FL
Calvin Thomas, ashley.thomas@neurology.ufl.edu -
University of Minnesota, Minneapolis, MN
John Martone, MDCenter@umn.edu -
University of Washington, Seattle, WA
Justine Marecaux, marecj@uw.edu, 206-685-2028 -
Montreal Neurological Institute and Hospital, Montreal, Quebec Canada
Smita Patel, nm.neurocru@mcgill.ca, 514-398-4097 -
Hôpital de Chicoutimi, Chicoutimi, Quebec, Canada
Marie-Josée Duchesne, Marie-josee.duchesne@ssss.gouv.qc.ca, 418-541-1000 ext 3163 -
NEW The Ottawa Hospital, Ottawa, Ontario, Canada
Jessica MacGregor, jemacgregor@ohri.ca, 613-798-5555, extension 19627
Not yet recruiting:
-
Beaumont Hospital, Royal Oak, MI
Coleen Tessmar, coleen.tessmar@beaumont.org -
University of North Carolina, Chapel Hill, NC
Said Alhassan, alhassan@neurology.unc.edu, 704-699-7393 -
University of Texas Health Science Center, San Antonio, TX
Yogeet Kaur, kaury@uthscsa.edu
Status:Recruiting
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystophy
Conditions: Congenital Myotonic Dystrophy, ages 6 to 16, can swallow or can take liquid study medicine by a gastronomy tube.
Location: Multiple sites
Sponsor: AMO Pharma Limited
Contact:
Recruiting:
- Little Rock, AR, Arkansas Children's Hospital
Annette Guy, 501-364-3380, guyea@archildrens.org - Palo Alto, CA, Stanford University
Stanford Neuromuscular Research, 650-725-4341, neuromuscularresearch@stanford.edu - Iowa City, IA, University of Iowa Hospitals and Clinics
Chandra Miller, 319-384-9618, chandra-miller@uiowa.edu - Rochester, NY, University of Rochester Medical Center
James Hilbert, 585-273-5590, james_hilbert@URMC.Rochester.edu
Jeanne Dekdebrun, 585-276-4611, jeanne_Dekdebrun@URMC.Rochester.edu - London, Ontario, Canada, Children's Hospital London Health Sciences Centre (LHSC)
Rhiannon Hicks, 519-685-8441, rhiannon.hicks@lhsc.on.ca - Ottawa, Ontario, Canada, Children's Hospital of Eastern Ontario
Emilie Hill Smith, 613-737-7600 ext 4014, EHillSmith@cheo.on.ca
Not yet recruiting:
- Los Angeles, CA, University of California, Los Angeles (UCLA)
- Pittsburgh, PA, Children's Hospital of the King's Daughters
- Pittsburgh, PA, Virginia Commonwealth University - Department of Neurology. Muscular Dystrophy Translational Research Program
- Newcastle Upon Tyne, United Kingdom, Newcastle University
Status: Recruiting
Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2 (BraCE-DM2)
Conditions: Confirmed and symptomatic DM2, Ages 35+, no history of active psychiatric and neurological disorders, can walk 10-meter independently (cane and walking sticks are permitted), be able to participate in an MRI, and not pregnant.
Location: Winston-Salem, NC
Sponsor: National Institute of Health (NIH)
Contact: Constance Linville, 336-716-4568, clinvill@wakehealth.edu
Status: Recruiting
Cognitive Function and Neuroimaging in Myotonic Dystrophy
Conditions: Males and females, ages 7 to 17 years-old, who have been diagnosed with CDM or childhood onset DM1.
Location: Salt Lake City, UT
Sponsor: University of Utah
Contact: Study Coordinator, Becky Crockett at 801-585-1676 or at becky.crockett@hsc.utah.edu
Status: Recruiting
Biomarker Development for Muscular Dystrophies
Conditions: Confirmed DM1 or DM2. Males and females ages 14 and older. In addition, male and female healthy volunteers ages 18 and older who are family members of an individual with muscular dystrophy also are invited to participate.
Location: Boston, MA
Sponsor: Massachusetts General Hospital
Contact: Thurman Wheeler, MD or Alex Sizemore, 617-726-7506
Status: Recruiting
Biomarker Development for Muscular Dystrophies
Conditions: Confirmed DM1 or DM2. Males and females ages 5 and older. In addition, male and female healthy volunteers ages 18 and older who are family members of an individual with muscular dystrophy also are invited to participate.
Location: Boston, MA
Sponsor:
- Boston Children's Hospital
- Massachusetts General Hospital
- Brigham and Women's Hospital
Contact:
- Thurman Wheeler, MD or Alex Sizemore, 617-726-7506
- Basil Darras, MD, or Rachael Titus, 617-919-1806
- Anthony Amato, MD, 857-307-1445
Status: Recruiting
Extracellular RNA biomarkers of myotonic dystrophy
Conditions: Confirmed DM1 or DM2. Males and females ages 5 and older. In addition, male and female healthy volunteers ages 18 and older who are family members of an individual with muscular dystrophy also are invited to participate.
Location: Boston, MA
Sponsor:
- Massachusetts General Hospital
- Brigham and Women’s Hospital
- Beth Israel Deaconess Medical Center
Contact:
- Thurman Wheeler, MD or Ningyan Hu, MS, 617-726-7506
- Marie Guthrie or Louis Beers, 857-307-1445
- Hilda Gutierrez, MD, 617-667-3086
Status: Recruiting
Study of Pathogenesis and Progression in DM (STOPP-DM2)
Conditions: DM2 ages 18-80 still open for enrollment; DM1 enrollment is closed
Location: University of Rochester, Rochester, NY
Sponsor: NIH
Contact: Jeanne Dekdebrun, M.S., (585)276-4611
Status: Recruiting
Myotonic Dystrophy Family Registry
Conditions: All types of DM
Location: Online/Global
Sponsor: Myotonic Dystrophy Foundation
Status: Recruiting
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Conditions: DM1; DM2; Congenital Myotonic Dystrophy; Muscular Dystrophy
Location: Rochester, NY
Sponsor:
- University of Rochester
- National Institute of Neurological Disorders and Stroke (NINDS)
Contact: Registry Coordinator, (888)925-4302
Status: Recruiting
Characterization of Sleep, Neuropsychology and Brain Changes in Adults with Myotonic Dystrophy Type 1
Conditions: DM1 and Unaffected
Location: Stanford, CA (Including Stanford Center for Sleep Sciences and Medicine)
Sponsor: NIH/Investigator-Initiated
Contact: Stanford Neuromuscular Research Line (650)725-4341
Status: Recruiting
Insulin Resistance and Insulin Secretion in Patients with Myotonic Dystrophy
Conditions: DM1
Location: Stanford, CA
Sponsor: Stanford University
Contact: Stanford Neuromuscular Research Line (650)725-4341
Status: Recruiting
Characterizing the Sleep and Gastrointestinal Changes in Adults with Myotonic Dystrophy (Questionnaire-based)
Conditions: Myotonic Dystrophy
Location: Stanford, CA
Sponsor: Stanford University
Contact: Stanford Neuromuscular Research Line 650-725-4341
Status: Recruiting
Venous Thromboembolism in Myotonic Dystrophy Type 1 (DM1-VTE)
Conditions: Myotonic Dystrophy Type 1
Location: Service de Cardiologie - Hôpital Cochin, France
Sponsor:
- Assistance Publique - Hôpitaux de Paris
- AFM-Téléthon (Funding)
- Recherche Clinique Paris Descartes Necker Cochin Sainte Anne
Contact:
- Karim Wahbi, MD, PhD; +33 (0)1 58 41 16 63; karim.wahbi@aphp.fr
- Adèle Bellino; +33 (0)1 58 41 11 95; adele.bellino@aphp.fr
Status: Recruiting
Sudden Cardiac Death Stratification in Myotonic Dystrophy Type 1 Patients
Conditions: Adults (18-75) with DM1 confirmed by genetic testing
Sponsor: University of Campania "Luigi Vanvitelli"
Status: Enrolling by invitation
Derivation of Human Induced Pluripotent Stem Cells to Heritable Cardiac Arrhythmias
Conditions: All types of DM
Location: Baltimore, MD
Sponsor: Johns Hopkins University
Status: Suspended (COVID-19)
Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy (TREAT-CDM)
Conditions: Children up to age 15 with Congenital Myotonic Dystrophy
Locations:
- Richmond, VA
- London, Ontario, Canada
- Milano, Italy, 20162
Sponsor:
- Virginia Commonwealth University
- Neuromuscular Omnicomprehensive Clinical Center
- University of Wetern Ontario
Contact:
- Nicholas Johnson, MD, (804)628-6439
- Brittney A Holmberg, (804)628-6439
Status: Active, not recruiting
Kennedy Krieger DM2 Natural History Study
Conditions: Adults (18+) with DM2 confirmed by genetic testing, LVEF >35% on two-dimensional echocardiography, and permanent pacing indication according to the current guidelines
Location: Baltimore, MD
Sponsor: Kennedy Kreiger Institute
Contact: Doris G. Leung, MD, PhD, (443)923-9521
Status: Active, not recruiting
Brain Structure and Function in Adults with a Family History of DM1
Conditions: Adults (18-65 years old) diagnosed with DM1 after the age of 21 or with a family history of DM1
Location: Iowa City, IA
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Status: Unknown
Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy
Conditions: Adults with DM1
Location: Mexico City, Mexico
Sponsor: National Institute of Respiratory Diseases, Mexico
Contact: Martha G Torres Fraga, MD, +(52)555 666 8640
Status: Unknown
Defining and Managing the Neuropsychological Abnormalities of Myotonic Dystrophy in Children
Conditions: DM1 and Unaffected
Location: Stanford, CA
Sponsor:
- Lucile Packard Children's Hospital
- Stanford University
Contact: Stanford Neuromuscular Research Line (650)725-4341
Status: Unknown
Muscle Relaxation in Myopathies With Positive Muscle Phenomena
Conditions: Adults with DM2
Location: Nijmegen, Netherlands
Sponsor: Radboud University
Contact: Baziel G van Engelen, MD, PhD, +(31)024 361 43 08
Status: Unknown
The Myotonic Dystrophy Type 1 (DM1) Deep Phenotyping to Improve Delivery of Personalized Medicine and Assist in the Planning, Design and Recruitment of Clinical Trials (PhenoDM1)
Conditions: DM1
Location: Newcastle and London
Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
Contact: Nikoletta Nikolenko, M.D., Ph.D., +4478 7051 7410
Status: Unknown
Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Ventilation in Adults with DM1
Conditions: DM1; myopathy; muscular weakness; respiratory insufficiency
Location: Paris, France
Sponsor: Assistance Publique - Hôpitaux de Paris
Status: Unknown
German Language Screening Questionnaire for Symptoms of Respiratory Muscle Weakness and Sleep-disordered Breathing in Patients With Neuromuscular Disorders
Conditions: German Adults (18-80 years old), All types of DM, patients without any type of home ventilatory support
Location: Münster, Germany
Sponsor: Westfälische Wilhelms-Universität Münster
Contact: Matthias Boentert, MD, +49-251-83 ext. 44458
Status: Unknown
Non Invasive Prenatal Testing of Single-Gene Disorders
Conditions: All types of DM
Location: Maastricht, Netherlands
Sponsor: Maastricht University Medical Center
Contact: Christine EM de Die, MD PhD, +31 4 33877859
Status: Completed
Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1
Conditions: Confirmed DM1. Ages 18-60 with the age of onset greater than 16. An Epworth Sleepiness Scale of >11 or participants who sleep an average >10 hours a day.
Location: Multiple sites
Sponsor: Expansion Therapeutics, Inc.
Contact: Anita Seto, PhD, 858-764-4290, info@expansionrx.com
-
Palo Alto, CA: Stanford, Dana McDonnell, danamc@stanford.edu, 650-407-7912
-
Miami, FL: Sleep Medicine Specialists of South Florida, Maria Almanzar, malmanzar@southfloridasleeps.com, 786-499-7786
-
Iowa City, IA: University of Iowa, Nicole Kressin, nicole-kressin@uiowa.edu, 319-678-8596
-
Chevy Chase, MD: Center for Sleep & Wake Disorders, Valmire Valcéna, valmire@sleepdoc.com, 301-654-5665
Status: Completed
Developmental Brain Disorders: Parent Survey of Symptoms and Function
Conditions: Children with genetic disorders that can result in autism, developmental and intellectual disability, seizures, challenging behaviors, movement disorders, vision/hearing loss, or any combination of these problems.
Location: Online Survey
Sponsor:
- University of Rochester, Rochester, NY
- Cardiff University, Cardiff, Wales, United Kingdom
Contact: DBDStudy@Cardiff.ac.uk or (585) 275-9330 (secure messages can be left at this number.)
Status: Completed
NIPD on CFTC for Triplet Repeat Diseases (DIACCIMEX)
Conditions: Expectant couple (pregnant woman between 9 and 34 weeks of gestation and her spouse) at risk of transmitting a triplet-repeat related genetic disease including Myotonic Dystrophy type 1
Location:
-
Bordeaux, France
-
Montpellier, France
-
Nice, France
-
Nîmes, France
-
Rennes, France
-
Saint Brieuc, France
-
Schiltigheim, France
-
Toulouse, France
-
Sponsor: University Hospital, Montpellier
Contact:
-
Marie Claire VINCENT, PhD-PharmaD, 411759879 ext 33
-
Claire GUISSART, 411759879 ext 33
Status: Completed
Clinical Outcome Measures in Myotonic Dystrophy Type 2 (COMEDY-2)
Conditions: Myotonic Dystrophy Type 2
Location: Friedrich-Baur-Institue, Dep. of Neurology Klinikum der Universitaet Muenchen Munich, Germany
Sponsor: Prof. Dr. Benedikt Schoser
Contact: Benedikt Schoser, MD
Status: Completed
Sleep Breathing Disorders, a Main Trigger for Cardiac Arrhythmias in Type 1 Myotonic Dystrophy
Conditions: DM1
Location: Grenoble, France
Sponsor: University Hospital, Grenoble
Contact: Amina Fontanell, +33 4 76 76 76 62
Clinical Trials FAQs
What are clinical trials?
Clinical trials are studies conducted using human participants to assess the safety and activity of new therapies in development. Clinical trials produce a lot of interest and excitement. It is important to realize, however, that just because an investigational compound is “tailor made” doesn’t mean that it will be safe or even effective; the purpose of a clinical trial is to find that out. This trial is an important first step, and all of us are interested in having it go well. Even if this medication does not work, we will learn as much as possible to guide the development of newer and better treatments in the future.
What are the different phases of clinical trials?
Clinical trials can be categorized into distinct phases depending upon the stage of clinical development of the drug. Phase I studies are the initial studies conducted in humans designed to primarily evaluate the safety and “pharmacokinetics” (the body’s reaction to a drug) in humans (often healthy humans). Phase II and III studies are larger, longer studies in affected individuals that continue to evaluate the safety of the drug as well as the activity and effectiveness of the drug prior to requesting regulatory agencies for marketing approval. Phase IV studies are studies designed to provide additional information about a drug that has been approved for marketing and is already available to qualified patients.
What is a placebo?
A placebo is an inactive drug administered to some of the patients (the placebo arm or control group) in a trial. This control group is essential as it provides a basis for comparison and for assessing the effects and efficacy of trial drugs. Well-controlled clinical studies, which often include placebo arms or groups, are necessary to establish the risk and benefit profile of the compound, as well as toevaluate the safety and tolerability of trial drugs.
What does "blinded" mean in a clinical trial?
A blinded clinical trial means you, your study doctor, and the study staff will not know if you have been given active drug or placebo. This helps to ensure that bias doesn't distort the conduct of the trial or the interpretation of the results.
Can trial participants discuss their results publicly?
We understand the community is eager to hear about results and the experiences of those participating, but sharing this information publicly can have a significant impact on the study, such as bias the results of a double-blind trial, potentially unblind the trial altogether, or even render the study inconclusive causing the trial to fail whether the treatment was effective or not. We know the community is anxious to get to effective treatments. We all have a role to play in making sure that we are supporting these clinical trial efforts.
For more information on discussing clinical trials publicly, please click here.
Resources for Study & Trial Participants
- Clinical Trials Training for Trial Participants
- Communications Behavior for Trial Participants
- An Ounce of Prevention: Social Media Discussions and Clinical Trial Threats
- Clinical Trials 101: What They Are, How They Work, Dr. Bruce Wentworth, Sarepta; Jeanne Dekdebrun, Elizabeth Luebbe, University of Rochester
- The US Drug Testing & Approval Process, Dr. Doug Kerr, Biogen Idec; related PowerPoint presentation
- The Clinical Trial: Real Life Experiences, Pat Furlong, Parent Project Muscular Dystrophy; related PowerPoint presentation
- How Antisense Oligoneucleotide Treatments are Designed to Work, Dr. Bruce Wentworth, Genzyme; related Powerpoint presentation
- DM Clinical Trial Readiness, Dr. Charles Thornton, University of Rochester; related PowerPoint presentation
If you have additional questions about the clinical trial process, please contact MDF.